Vanguard Group
ENSC icon

Vanguard Group’s Ensysce Biosciences ENSC Stock Holding History

Vanguard Group’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$33.8K Hold
36,708
– – ﹤0.01% 4281
2025
Q3 		$87K Buy
+36,708
New +$79K ﹤0.01% 4243
2024
Q4 		– Sell
-1,212
Closed -$4.36K – 4303
2024
Q3 		$4.36K Hold
1,212
– – ﹤0.01% 4340
2024
Q2 		$9.21K Hold
1,212
– – ﹤0.01% 4393
2024
Q1 		$14.4K Hold
1,212
– – ﹤0.01% 4411
2023
Q4 		$19.3K Buy
1,212
+184
+18% +$2.96K ﹤0.01% 4448
2023
Q3 		$21.3K Hold
1,028
– – ﹤0.01% 4493
2023
Q2 		$27.8K Buy
+1,028
New +$46.5K ﹤0.01% 4502
2022
Q4 		– Sell
-88
Closed -$68K – 4536
2022
Q3 		$68K Buy
88
+54
+159% +$88K ﹤0.01% 4520
2022
Q2 		$106K Hold
34
– – ﹤0.01% 4541
2022
Q1 		$140K Sell
34
-50
-60% -$331K ﹤0.01% 4576
2021
Q4 		$1.42M Buy
+84
New +$792K ﹤0.01% 4161

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's ENSC Position: Q4 2025 in Review

Vanguard Group held its Ensysce Biosciences (ENSC) position steady in Q4 2025 at 36,708 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4281.

Vanguard Group first reported a position in ENSC in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.42M in Q4 2021. 17 funds tracked by Wall St. Rank hold ENSC as of Q4 2025.

  • Vanguard Group held 36,708 shares of Ensysce Biosciences worth $33.8K as of Q4 2025.
  • Vanguard Group left its Ensysce Biosciences share count unchanged in Q4 2025.
  • Ensysce Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4281 holding.
  • Vanguard Group first reported a position in Ensysce Biosciences in Q4 2021 and has held it in 12 quarters since.
  • Vanguard Group's Ensysce Biosciences position peaked at $1.42M in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.